MainpointsLitifilimab demonstrates a favorable probability of success and upside potential in its Phase III trial for ...

The 7MM Cutaneous Lupus Erythematosus treatment market was valued at approximately USD 970 million in 2025 and is projected to reach approximately USD 4.3 billion by 2036, growing at a CAGR of ...

Richie Mo’unga has been ruled out after suffering a calf injury during All Blacks training, dealing New Zealand a significant ...

Nearly 1 in 3 patients with systemic lupus erythematosus (SLE) are taking a supplement-medication combination with potential ...

A multicenter study led by researchers at Sultan Qaboos University has found that patients with a rare inherited form of ...

Researchers in Pakistan trained deep learning models to distinguish four histopathologically similar inflammatory skin ...

To access the live webcast of the call, please visit the “ Events and Presentations ” page in the Investor & Media Relations section of the Zenas BioPharma website. A replay of the webcast will be ...

Thoughts on Iron-Blood CoatingThis is the production of the HG Barbatos Lupus I announced last week. This time, I decided on ...

Results from the Phase 3 part of AMETHYST are expected in the first half of 2027; in January 2026 the FDA granted ...

Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of ​autoimmune disease in a mid-stage study.

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...